TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16163089

Group type: EXPERIMENTAL
Intervention: Topical negative-pressure therapy with no interface dressing
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Topical negative-pressure therapy with Vaseline-impregnated gauze
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Topical negative-pressure therapy with nonadherent silicone dressing
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Topical negative-pressure therapy with mylar polyester film dressing
Number of subjects: 40
Study: 12393106

Group type: EXPERIMENTAL
Intervention: Warfarin prophylaxis and epidural analgesia
Number of subjects: 52
Study: 10102328

Group type: EXPERIMENTAL
Intervention: Colorimetric end-tidal CO2 (ETCO2) detector (EASY CAP)
Number of subjects: 121
Study: 7586476

Group type: EXPERIMENTAL
Intervention: Ultrathin hydrogel lenses (0.04 mm, 67% water content)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard thickness hydrogel lenses (0.12 mm)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ultrathin hydrogel lenses
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ultrathin hydrogel lenses and Standard thickness lenses
Number of subjects: 20
Study: 1874490

Group type: EXPERIMENTAL
Intervention: Chenodiol therapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (similar chenodiol doses, no liver injury)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy subjects (n = 45)
Number of subjects: 31
Study: 7318640

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31070709

Group type: EXPERIMENTAL
Intervention: ASP8273
Number of subjects: 530

Group type: COMPARATOR
Intervention: Erlotinib/gefitinib
Number of subjects: 530
Study: 27867080

Group type: EXPERIMENTAL
Intervention: Rom-PLIF (robot-assisted, minimally invasive posterior lumbar interbody fusion)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Cop-PLIF (conventional, freehand, open approach posterior lumbar interbody fusion)
Number of subjects: 78
Study: 26491868

Group type: EXPERIMENTAL
Intervention: Individuals with radiological OA and 'mild' overall symptoms on the WOMAC score
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Individuals with clinical OA and 'severe' overall symptoms
Number of subjects: 389
Study: 23474008

Group type: EXPERIMENTAL
Intervention: Far infrared therapy (40 minutes, 3 times weekly for a year)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Far infrared therapy
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 122
Study: 21357380

Group type: EXPERIMENTAL
Intervention: High isoflavone intake (>16.3 mg isoflavones)
Number of subjects: 3088

Group type: EXPERIMENTAL
Intervention: Increasing isoflavone intake
Number of subjects: 3088
Study: 19303721

Group type: EXPERIMENTAL
Intervention: Brachytherapy
Number of subjects: 226
Study: 17050010

Group type: EXPERIMENTAL
Intervention: Intracoronary stem cell therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 46
Study: 15499530

Group type: EXPERIMENTAL
Intervention: Colostrum from vaccinated mothers
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 16
Study: 11564574

Group type: EXPERIMENTAL
Intervention: Patient Information Leaflet (PIL) provided
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control group (leaflet absent)
Number of subjects: 800
Study: 9973149

Group type: EXPERIMENTAL
Intervention: Amitriptyline (AMI; 25-37.5 mg)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Moclobemide (MOCLO; 450-600 mg)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 7977094

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 14124

Group type: EXPERIMENTAL
Intervention: Standard dose t-PA
Number of subjects: 14124

Group type: EXPERIMENTAL
Intervention: Accelerated dose t-PA
Number of subjects: 14124

Group type: EXPERIMENTAL
Intervention: Anistreplase (APSAC)
Number of subjects: 14124

Group type: COMPARATOR
Intervention: t-PA
Number of subjects: 14124

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 14124
Study: 2908486

Group type: EXPERIMENTAL
Intervention: 10 mg cetirizine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 60 mg terfenadine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control saline solution
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Histamine: aqueous solution (Hsol)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Histamine: prick test (Hprick)
Number of subjects: 10
Study: 30101416

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine (CHX) solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine (CHX) + hyaluronic acid (HA) + antidiscoloration system (ADS)
Number of subjects: 0
Study: 27531660

Group type: EXPERIMENTAL
Intervention: iTClamp
Number of subjects: 13

Group type: COMPARATOR
Intervention: Combat Application Tourniquet (CAT)
Number of subjects: 13
Study: 23549653

Group type: EXPERIMENTAL
Intervention: Online evidence-based patient information (EBPI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard patient information
Number of subjects: 0
Study: 23951692

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 microg/kg over 10 minutes at anesthesia induction, followed by 0.4 to 0.8 microg/kg per hour infusion during maintenance
Number of subjects: 66

Group type: COMPARATOR
Intervention: Remifentanil 1 microg/kg over 1 minute at anesthesia induction, followed by 0.2 to 0.4 microg/kg per minute infusion during maintenance
Number of subjects: 66
Study: 19933801

Group type: EXPERIMENTAL
Intervention: S-013420 (EDP-420)
Number of subjects: 28
Study: 17967217

Group type: EXPERIMENTAL
Intervention: Iron supplementation (20 mg daily)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 430
Study: 16004022

Group type: EXPERIMENTAL
Intervention: Ciclopirox nail lacquer once daily for 48 weeks plus 4 weeks of terbinafine 250 mg/day, followed by 4 weeks of rest (no terbinafine), then another 4 weeks of terbinafine 250 mg/day (PLs)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Ciclopirox nail lacquer once daily for 48 weeks plus terbinafine 250 mg/day for 12 weeks (PL12)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Terbinafine 250 mg/day for 12 weeks (L12)
Number of subjects: 73
Study: 12855874

Group type: EXPERIMENTAL
Intervention: Intramedullary nailing (I degrees FN)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Damage control orthopedic surgery and external fixation (DCO I degrees Ex.fix.)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Damage control orthopedic surgery and external fixation (DCO II degrees FN)
Number of subjects: 35
Study: 9892253

Group type: EXPERIMENTAL
Intervention: Glycine (0.8 g/kg per day)
Number of subjects: 22
Study: 9050688

Group type: EXPERIMENTAL
Intervention: Goserelin 3.75 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 13
Study: 1931396

Group type: EXPERIMENTAL
Intervention: Clonidine 2 micrograms kg‐1 i.v. administered over 20 min
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isotonic saline solution
Number of subjects: 20
Study: 399527

Group type: EXPERIMENTAL
Intervention: Inhaled prostacyclin (PGI2)
Number of subjects: 10
Study: 31001633

Group type: EXPERIMENTAL
Intervention: 15/50 VLP vaccine formulation (15 µg of GI.1 and 50 µg of GII.4c VLPs)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: 50/50 VLP vaccine formulation (50 µg of GI.1 and 50 µg of GII.4c VLPs)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Memory probe vaccination (15 µg each of GI.1 and GII.4c VLPs with Al(OH)3)
Number of subjects: 454

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 454
Study: 28573476

Group type: EXPERIMENTAL
Intervention: Single fraction radiotherapy (8 Gy × 1 fraction)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Multifraction radiotherapy (3 Gy × 10 fractions)
Number of subjects: 101
Study: 25403645

Group type: EXPERIMENTAL
Intervention: 4F‐PCC 50 IU/kg
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 4F‐PCC 25 IU/kg
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 4F‐PCC 10 IU/kg
Number of subjects: 110

Group type: COMPARATOR
Intervention: Edoxaban 60 mg
Number of subjects: 110
Study: 23276801

Group type: EXPERIMENTAL
Intervention: Weight-bearing (WB) exercise
Number of subjects: 29

Group type: COMPARATOR
Intervention: Nonweight-bearing (NWB) exercise
Number of subjects: 29
Study: 20530591

Group type: EXPERIMENTAL
Intervention: α‐methylparatyrosine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 19861667

Group type: EXPERIMENTAL
Intervention: Liquid-based cytology
Number of subjects: 89784

Group type: COMPARATOR
Intervention: Conventional Pap test
Number of subjects: 89784
Study: 17364311

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (40 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Misoprostol (200 microg)
Number of subjects: 120
Study: 15160251

Group type: EXPERIMENTAL
Intervention: Cleft patients (UCLP and BCLP)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Non-cleft controls
Number of subjects: 23
Study: 11817713

Group type: EXPERIMENTAL
Intervention: 16-week progressive high-intensity strength training (HIST) program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group maintaining habitual physical activity
Number of subjects: 30
Study: 9742478

Group type: EXPERIMENTAL
Intervention: Pediatric powder formulation of didanosine (ddI)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Buffered didanosine (ddI) tablets
Number of subjects: 20
Study: 8061335

Group type: EXPERIMENTAL
Intervention: Triple therapy (bismuth subcitrate 120 mgx4 + amoxycillin 500 mgx4 + metronidazole 250 mgx4)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Double therapy (amoxycillin 500 mgx4 + metronidazole 250 mgx4)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Double therapy
Number of subjects: 46
Study: 2564267

Group type: EXPERIMENTAL
Intervention: Aerosolized thiazinamium chloride (TC) 300 micrograms
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Aerosolized thiazinamium chloride (TC) 600 micrograms
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Aerosolized thiazinamium chloride (TC) 900 micrograms
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Active control drug (metaproterenol or cromolyn)
Number of subjects: 15
Study: 4121478

Group type: EXPERIMENTAL
Intervention: Hydromorphone (1.25 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydromorphone (0.95 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine (10 mg)
Number of subjects: 0
Study: 31373222

Group type: EXPERIMENTAL
Intervention: HEART Camp intervention
Number of subjects: 204

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 204
Study: 30941931

Group type: EXPERIMENTAL
Intervention: cTTE (contrast transthoracic echocardiography)
Number of subjects: 0

Group type: COMPARATOR
Intervention: cTCD (contrast transcranial Doppler)
Number of subjects: 0

Group type: COMPARATOR
Intervention: cTCD
Number of subjects: 0
Study: 28332420

Group type: EXPERIMENTAL
Intervention: Intervention group (informed of 6-month follow-up at fitting)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control group (informed just prior to follow-up)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Datalogging (objective assessment)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Self-report (subjective assessment)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: More severe hearing impairment and prior hearing aid experience
Number of subjects: 181
Study: 26135276

Group type: EXPERIMENTAL
Intervention: School-based prevention manual
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic public health intervention
Number of subjects: 0
Study: 23275081

Group type: EXPERIMENTAL
Intervention: Posterior-stabilised (PS) TKA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cruciate-retaining (CR) TKA
Number of subjects: 40
Study: 21480732

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches (7 mg/24 h)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 18639300

Group type: EXPERIMENTAL
Intervention: Double layer urethrovesical anastomosis
Number of subjects: 116

Group type: COMPARATOR
Intervention: Single layer urethrovesical anastomosis
Number of subjects: 116
Study: 17354095

Group type: EXPERIMENTAL
Intervention: Ultrasonic scaling + subgingival irrigation with 0.5% PVP-iodine for 5 min/tooth
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ultrasonic scaling + subgingival irrigation with sterile saline solution for 5 min/tooth
Number of subjects: 20

Group type: COMPARATOR
Intervention: Subgingival irrigation with sterile saline solution for 5 min/tooth
Number of subjects: 20

Group type: COMPARATOR
Intervention: Subgingival irrigation with 0.5% PVP-iodine for 5 min/tooth
Number of subjects: 20
Study: 14977032

Group type: EXPERIMENTAL
Intervention: Participants who committed a mock theft of a dollar and were asked questions about an outside issue
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Participants who committed a mock theft of a dollar and were not asked questions about an outside issue
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Participants who did not commit a mock theft and were asked questions about an outside issue
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Participants who did not commit a mock theft and were not asked questions about an outside issue
Number of subjects: 192
Study: 11291467

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9512672

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin and vinblastine followed by radiotherapy and concomitant carboplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard regional therapy with radiotherapy and surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy, surgery, and radiotherapy (previously piloted approach)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paclitaxel, gemcitabine, and vinorelbine in combination with cisplatin
Number of subjects: 0
Study: 7844211

Group type: EXPERIMENTAL
Intervention: 16 beta‐methylprednisolone (0, 16 or 60 mg/day) for 4 days from the day of oocyte retrieval
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no corticosteroid treatment)
Number of subjects: 0
Study: 3348163

Group type: EXPERIMENTAL
Intervention: Fluoride supplementation (10 or 20 mg F/d as sodium fluoride) during bed rest weeks 6-10
Number of subjects: 15

Group type: COMPARATOR
Intervention: Bed rest (weeks 6-10)
Number of subjects: 15
Study: 30558466

Group type: EXPERIMENTAL
Intervention: myo‐inositol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: d‐chiro‐inositol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: myo‐inositol/D‐chiro‐inositol
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 31037967

Group type: EXPERIMENTAL
Intervention: Olaparib maintenance therapy after first-line chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo maintenance therapy after first-line chemotherapy
Number of subjects: 0
Study: 30020266

Group type: EXPERIMENTAL
Intervention: Adhesive bone conduction hearing system
Number of subjects: 17

Group type: COMPARATOR
Intervention: CROS hearing aid
Number of subjects: 17
Study: 26518420

Group type: EXPERIMENTAL
Intervention: 3-month dual antiplatelet therapy (DAPT) after CoCr-EES implantation
Number of subjects: 1525

Group type: EXPERIMENTAL
Intervention: 3-month DAPT after CoCr-EES implantation
Number of subjects: 1525
Study: 25524969

Group type: EXPERIMENTAL
Intervention: Whey protein plus potassium bicarbonate supplement
Number of subjects: 10

Group type: COMPARATOR
Intervention: No supplement (control)
Number of subjects: 10
Study: 22215056

Group type: EXPERIMENTAL
Intervention: Clinical alert directed to the provider suggesting adding a problem to the electronic problem list based on inference rules.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no clinical alert).
Number of subjects: 28
Study: 19091800

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (1.5 g/d (n‐3) LCPUFA)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Olive oil (OO) supplementation
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation
Number of subjects: 122
Study: 17628346

Group type: EXPERIMENTAL
Intervention: Project EX-4 intervention (8 session classroom-based curriculum)
Number of subjects: 1097

Group type: COMPARATOR
Intervention: Control condition (standard care)
Number of subjects: 1097
Study: 16225529

Group type: EXPERIMENTAL
Intervention: Intravesical sodium hyaluronate (6 weekly doses)
Number of subjects: 38
Study: 12192465

Group type: EXPERIMENTAL
Intervention: Short-term training of GPs (half a day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (7 GPs, no training)
Number of subjects: 16
Study: 9789914

Group type: EXPERIMENTAL
Intervention: Population based smoothing methods derived from a random‐effects model plus a stochastic process or individual based smoothing methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imputes in a time‐dependent Cox model
Number of subjects: 0
Study: 8131242

Group type: EXPERIMENTAL
Intervention: Naproxen sodium (275 mg x 2 capsules, total 550 mg)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 2680272

Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce calorie intake
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce sodium intake
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce sodium and calorie intake
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce sodium and increase potassium intake
Number of subjects: 841

Group type: COMPARATOR
Intervention: Control group (no dietary counseling)
Number of subjects: 841
Study: 30343590

Group type: EXPERIMENTAL
Intervention: IA-PRP injections (2 ultrasound-guided injections)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Corticosteroids (2 ultrasound-guided intra-articular methylprednisolone and lidocaine injections at a 2-week interval)
Number of subjects: 33
Study: 31192569

Group type: EXPERIMENTAL
Intervention: Total activity energy expenditure
Number of subjects: 2888

Group type: EXPERIMENTAL
Intervention: Sum of vigorous-intensity physical activity (PA)
Number of subjects: 2888

Group type: EXPERIMENTAL
Intervention: Sum of moderate activity energy expenditure
Number of subjects: 2888

Group type: EXPERIMENTAL
Intervention: Non-leisure-time physical activity (PA)
Number of subjects: 2888

Group type: EXPERIMENTAL
Intervention: Sleep duration
Number of subjects: 2888

Group type: EXPERIMENTAL
Intervention: Vegetable intake
Number of subjects: 2888
Study: 28239919

Group type: EXPERIMENTAL
Intervention: MiQuit (text message intervention)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 407
Study: 25157964

Group type: EXPERIMENTAL
Intervention: ECT plus clozapine
Number of subjects: 39

Group type: COMPARATOR
Intervention: Clozapine
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Crossover phase (ECT after clozapine nonresponse)
Number of subjects: 39
Study: 23219613

Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM) of the ankle joint for 1 hour a day, 5 days a week for 4 weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM) of the ankle joint
Number of subjects: 14
Study: 22018126

Group type: EXPERIMENTAL
Intervention: 0.03 mg ethinyl estradiol and 3 mg drospirenone 21/7 regimen (Group 1) for 6 months
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.02 mg ethinyl estradiol and 3 mg drospirenone 24/4 regimen (Group 2) for 6 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study: 18649072

Group type: EXPERIMENTAL
Intervention: DMT
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: S-ketamine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 16574042

Group type: EXPERIMENTAL
Intervention: Mobilization
Number of subjects: 103

Group type: COMPARATOR
Intervention: Immobilization
Number of subjects: 103
Study: 12783230

Group type: COMPARATOR
Intervention: Backpack of 0% body mass
Number of subjects: 15

Group type: COMPARATOR
Intervention: Backpack of 10% body mass
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Backpack of 15% body mass
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Backpack of 20% body mass
Number of subjects: 15
Study: 10714852

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA) with propofol and alfentanil
Number of subjects: 20

Group type: COMPARATOR
Intervention: Peribulbar local block
Number of subjects: 20
Study: 8956797

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 40 mg m-2 + Etoposide (VP16) 100 mg m-2 on days 1-3 (arm A)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Cisplatin (CDDP) 30 mg m-2 on days 2 and 3 + Carboplatin (CBDCA) 250 mg m-2 on day 1 + Etoposide (VP16) 100 mg m-2 on days 1-3 + Vinorelbine (NVB) 30 mg m-2 on day 1 (arm B)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Experimental regimen (arm B)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Standard regimen (arm A)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control regimen (arm A)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 112
Study: 1525748

Group type: EXPERIMENTAL
Intervention: Increased fluid intake (50% more than normal)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Decreased fluid intake (50% less than normal)
Number of subjects: 10
Study: 2410317

Group type: EXPERIMENTAL
Intervention: Sucrose (24 +/- 13 g/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sodium cyclamate (348 +/- 270 mg/day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sodium cyclamate
Number of subjects: 10
Study: 29301920

Group type: EXPERIMENTAL
Intervention: Warfarin for 18 months
Number of subjects: 371

Group type: COMPARATOR
Intervention: Placebo for 18 months
Number of subjects: 371
Study: 27922214

Group type: EXPERIMENTAL
Intervention: Tier One Word Generation (WG) program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tier Two Strategic Adolescent Reading Intervention (STARI)
Number of subjects: 0